Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realization of the above-mentioned project.

Egis Pharmaceuticals PLC acquired Sinuforte from Hartington Business S.L. Under the agreement Egis receives all rights related to the product, a nasal spray indicated for the treatment of sinusitis and other inflammatory diseases of the paranasal sinuses. The company seeks to ensure its growing presence in major export markets through organic growth and targeted acquisitions.

Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets.

Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.

EGIS-RUS received the honor from Aon Hewitt, the global leader in human resource solutions and its Russian partner AXES Management

Egis Pharmaceuticals has been awarded „Family-friendly workplace”, founded by the Ministry of Human Capacities.

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

We inform our customers, partners and consumers about the change packaging design of more than 30 products.

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.

One of the pillars of our corporate culture is innovation. We do not only talk about it, but enjusre the flow of ideas with annual forums that offer space for making proposals in connection with scientific research, manufacturing, how to make our administrative process more effective and the latest item on our agenda: digitalization.

New Year is a time of miracles and cherished wishes, it is essentially about and for children. Therefore, EGIS-RUS decided to give them a charity Christmas Tree “Chain of Good”. On December 21, 2019, EGIS-RUS’ office opened its doors for the children of the employees and young guests from the orphanage in Moscow.

Egis Russia’s Buy for Good campaign that was carried out in 2018 won the award of ‘Best Social Projects in Russia’ in the category of medical and social projects.

Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life. Each and every employee is important and valuable to us.

From October 7 to December 22, 2019, there will be a TV broadcasting campaign in support of Sinuforte®. The commercial under the slogan “Do not let sinusitis cling on to you” is broadcasting on the largest federal television channels: Russia, TNT, Muz-TV, Friday, Channel 5, TV-3, Disney, U.

In close cooperation with our employees, we're currently working on redesigning our protective clothing. Though the project is still in progress, our collaboration was already acknowledged: we were awarded the Healthy Workplaces Good Practice Award, so we can move on to the next round organized for EU countries.

With programs focusing on counseling and prevention, Egis was present on the Day of Vascular Diseases.